Innervate Therapeutics
Developer of a gene therapy platform for neurorestorative treatments targeting motor neurone disease, spinal cord injury and Parkinson’s disease. The company focuses on engineering a neurotrophic factor isoform and a CNS-focused gene delivery approach, advancing programs through preclinical development toward first-in-human studies.
Industries
Nr. of Employees
small (1-50)
Products
CNS gene therapy platform for neurorestoration
A proprietary gene delivery platform designed to deliver a neurotrophic factor isoform to the CNS, developed to treat motor neurone disease, spinal cord injury and Parkinson’s disease.
CNS gene therapy platform for neurorestoration
A proprietary gene delivery platform designed to deliver a neurotrophic factor isoform to the CNS, developed to treat motor neurone disease, spinal cord injury and Parkinson’s disease.
Services
Management and execution of preclinical efficacy and safety programs to support translational progression of CNS gene therapies toward clinical entry.
Planning and preparation services for first-in-human study design, timelines, and investor-facing materials to support early-phase clinical entry.
Management and execution of preclinical efficacy and safety programs to support translational progression of CNS gene therapies toward clinical entry.
Planning and preparation services for first-in-human study design, timelines, and investor-facing materials to support early-phase clinical entry.
Expertise Areas
- Gene therapy development
- Neurorestorative therapeutics
- Translational neuroscience
- Preclinical development and IND-enabling studies
Key Technologies
- Gene therapy platforms
- Recombinant protein / isoform engineering
- Neurosurgical intracerebral infusion techniques
- Neurotrophic factor–based therapeutics
News & Updates
The company reports its gene therapy program for motor neurone disease is in advanced preclinical development with a first-in-human study planned for 2027.
Preclinical development for a spinal cord injury indication is planned to commence in 2025 with a target to initiate a first-in-human study in 2027.
A Parkinson’s disease indication using the same gene therapy platform is reported to be entering preclinical development imminently.
A non-confidential executive summary / information memorandum (November 2024) is available for potential investors.
The company reports its gene therapy program for motor neurone disease is in advanced preclinical development with a first-in-human study planned for 2027.
Preclinical development for a spinal cord injury indication is planned to commence in 2025 with a target to initiate a first-in-human study in 2027.
A Parkinson’s disease indication using the same gene therapy platform is reported to be entering preclinical development imminently.
A non-confidential executive summary / information memorandum (November 2024) is available for potential investors.